

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Carfilzomib with dexamethasone and lenalidomide for  
previously treated multiple myeloma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Consultation**

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equalities issues were identified during the scoping process.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equalities issues were raised.
-----------------------------------

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.
-----

- |  |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The patient expert confirmed that there are no known equality issues relating to this appraisal.

**Approved by Associate Director (name):** Jo Holden

**Date:** 21/07/2020

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Stakeholders highlighted that if carfilzomib plus lenalidomide and dexamethasone was to be recommended in patients who are lenalidomide naïve, then this could potentially disadvantage those who have received prior lenalidomide at first-line as part of a clinical trial. Whilst this is not considered to be an equality issue, the recommendations made by the committee are not optimised based on exposure to prior lenalidomide. The committee recognised that the myeloma pathway is continuously evolving and that first-line treatments may change in the future.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote

equality?
Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
See section 3.14 of the FAD

**Approved by Associate Director (name):** .....Ross Dent.....

**Date:** 28/01/21